Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of GS1-144 for moderate to severe vasomotor symptoms in postmenopausal women in China
CTR20243474Phase 2Completed
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of GS1-144 in vasomotor symptoms, sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Started Sep 2024; status: completed.
02
Drugs
GS1-144
03
Conditions
vasomotor symptoms
Beyond the preview
Go deeper on CTR20243474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243474.